Clinical Study
Mild to moderate Alzheimer's Disease (IV-1)
The Butler Hospital Memory & Aging Program is conducting a clinical research study of an intravenously-administered, investigational drug called bapineuzumab (IV-1). This study tests whether the investigational drug IV-1 safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD).
Qualified participants must be:
- from 50 to 88 years of age
- diagnosed with mild to moderate Alzheimer's disease
- not taking Coumadin®
- accompanied by a regular caregiver to 15 study visits over a 1.5-year period
For more information please call 401-455-6403 or read our brochure!
All inquiries are confidential.
Butler Hospital's Memory and Aging Program Seeks Study Volunteers with
Alzheimer’s Disease
ICARA
Study to evaluate safety and effectiveness of an investigational drug
for
controlling progression of Alzheimer’s disease
5/01/2008 — The Memory and Aging Program at Butler Hospital is participating in ICARA (Investigational
Clinical Amyloid Research in Alzheimer’s) – an international clinical study to
learn if an investigational drug can help control the progression of
Alzheimer’s disease. In total,
approximately 2050 patients will be enrolled at research sites in
Alzheimer’s
disease is a neurodegenerative disorder characterized by progressive loss of
memory and cognitive function. It destroys
brain cells, causing problems with memory, thinking and behavior severe enough
to affect everyday life. Alzheimer’s gets worse over time, and it is
fatal. Alzheimer’s is the most common cause of dementia in the elderly, affecting approximately
18 million people worldwide. Alzheimer’s-related medical complications are
among the most common causes of death in the elderly population.
“Our goal
is to explore if this investigational drug can help control the progression of
Alzheimer’s. Most current therapies for
Alzheimer’s treat the symptoms associated with it and not the disease itself,”
said Dr. Stephen Salloway. “It is important for
patients and families affected by Alzheimer’s to consider participating in
clinical studies. Clinical studies that test new treatments are the best chance
we have for fighting this disease.”
Participants for the ICARA study must be between 50 and 88 years
of age, have a diagnosis of mild to moderate Alzheimer’s disease and have a
caregiver who is willing to be involved in the study. A medical team including a nurse or study
coordinator and a physician will monitor participants throughout the study.
More information about the study is available
by calling 401-455-6403.
